Outcomes in B cell non-Hodgkin lymphoma patients who underwent autologous stem cell transplantation following rituximab containing conditioning regimens.
Study #: LY18-01a
Study Status: Published
Presentation(s)
2019, ASH (Oral)
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Citation
Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M.
Cancer. 2020, May 15: 126(10): 126(10):2279-2287. doi: 10.1002/cncr.32752. Epub 2020, Feb 12. PMCID:PMC7190439.
PubMed
PMID: 32049359
Abstract